

Edwards Lifesciences

Closing Remarks



2018 Expected to be a Year of Continued Growth and Investment in Our Future

Underlying sales growth of **9-10%**

R&D **~16%** of sales to drive value creation

Adjusted EPS of **\$4.10 - \$4.30**

Continued growth in the treatment of AS through TAVR

Momentum in **multiple breakthrough** structural heart valve therapies

Innovation in our **core leadership franchises** of SHVT and CC

Continued investments:

- Expansion of TAVR
- Transcatheter mitral and tricuspid therapies
- Capacity and infrastructure

* Growth rates and EPS are estimated

Planned 2018 Milestones Fuel Future Growth

Transcatheter Heart Valves

- SAPIEN 3 Ultra EU launch
- SAPIEN 3 Ultra U.S. launch
- CENTERA EU launch
- Initiate CENTERA U.S. trial

Surgical Heart Valves

- Harpoon EU launch
- Initiate Harpoon U.S. trial
- INSPIRIS U.S. launch
- INSPIRIS Japan launch

Transcatheter Mitral & Tricuspid Therapies

- Complete PASCAL CLASP mitral CE Mark trial
- Initiate PASCAL mitral U.S. trial
- Cardioband tricuspid CE Mark
- Initiate Cardioband tricuspid U.S. trial

Critical Care

- Launch HemoSphere phase 2
- U.S. approval of HPI
- Initiate U.S. Assisted Fluid Management trial


Transcatheter Heart Valve Therapy



Despite the rapid adoption of TAVR, less than 1 in 5 severe AS patients receives valve replacement therapy

Global TAVR opportunity beyond 2021 is significant

Surgical Heart Valve Therapy



SHVT will advance its core aortic leadership, while focusing on transforming mitral therapies and expanding into strategic markets

Focused on reaching more patients and elevating surgery


Transcatheter Mitral and Tricuspid Therapies



Transforming the care of patients with mitral and tricuspid regurgitation through an advanced toolbox

An estimated \$3B+ opportunity by 2025

Critical Care




We are building upon our heritage of leadership to create the future with HemoSphere, predictive monitoring solutions and expanding ESR adoption with ClearSight

Critical Care products can benefit millions more patients per year

Edwards is Committed to Good Corporate Citizenship

- Strengthening the **trust of our stakeholders, partners and communities**
- Our **sustainability** goals and results are aligned with our Aspirations
- We report on our sustainability at **Edwards.com**



A Message from Our Chairman and CEO

I am pleased to welcome you to Edwards Lifesciences' 2016 Sustainability Report. While we continue to enhance our reporting efforts, we have stayed true to our company's commitments to helping patients, acting as responsible corporate citizens and advancing the trust of our stakeholders, partners and communities—commitments that are long-held and strong. It begins with Our Credo, which guides our values, spirit and conscience in everything that we do, and forms the framework for our Aspirations, which are the goals that inspire our more than 11,000 talented global employees every day.

Our Credo and Aspirations help us define our annual strategic priorities and objectives. We align our sustainability reporting efforts to our Aspirations, as they represent the relationships and

Edwards and its Board are Committed to Good Corporate Governance

- A strong and **independent board**
- **Leading governance** practices
- Frequent stockholder **engagement**
- **Performance-based compensation** philosophy based on:
 - Financial performance
 - Key Operating Drivers
 - Shareholder value creation



Michael A. Mussallem



Kieran T. Gallahue



Leslie S. Heisz



William J. Link Ph.D.



Steven R. Loranger



Martha H. Marsh



Wesley W. von Schack



Nicholas J. Valeriani

Edwards Lifesciences Philanthropy

- **Every Heartbeat Matters** initiative to impact global burden of heart valve disease among underserved
- On-track to educate, screen or treat one million underserved people by 2020
- We **support the communities** where we live and work
 - Aspiration for 100% employee participation




Edwards Lifesciences

Edwards' Patient Focused Innovation Strategy


Focus

Singular focus on the large unmet needs of structural heart and critically ill patients




Innovation

Pioneer breakthrough technologies with superior evidence



Leadership

Lead groundbreaking standards of care through trusted relationships




























Create meaningful value by transforming patient care

12/7/17 11

Edwards Lifesciences

Unmatched Pipeline Driving Durable Growth

	THVT	SHVT	TMTT	CC			
	 SAPIEN 3 Ultra	 CENTERA	 SAPIEN Evolutionary	 SAPIEN Revolutionary	 Alterra	 THE PARTNER 3 TRIAL	 THE EARLY TAVR TRIAL
	 INSPIRIS	 Harpoon EU	 INTUITY Elite	 KONECT AVC	 MultiShot	 Harpoon U.S.	 New Mitral*
	 Cardioband MR	 CardiAQ*	 Cardioband TR	 PASCAL MR EU	 SAPIEN M3* (S3 with dock)	 FORMA	 PASCAL MR U.S.
	 HemoSphere All-in-One Platform	 FloTrac Hypotension Prediction	 ClearSight Assisted Fluid Management	 Next Gen Capital Platform*			

*Illustrative purposes only. Products not available for commercial sale, except Cardioband MR, HemoSphere, INSPIRIS and INTUITY Elite.

12/7/17 12

Edwards is Poised for Long-Term Success

- Unwavering **patient-focused culture** motivates and guides our global team
- **Differentiated strategy** based on focus, innovation and leadership
- **Innovative R&D** to produce breakthrough therapies
- **Credibility and trust** with clinicians, regulators, payors and patients
- **Nimble and adaptive** business model
- Well positioned for significant **global growth**

Addressing significant patient needs creates exceptional shareholder value

Q&A



Patient Video

Mario



Edwards

Helping Patients is Our Life's Work, and
life is now